Carlsquare Equity Research has updated its research report on DanCann Pharma.
 
Interesting acquisition brings shortcut to the market.
 
Read the full analysis here.

About Carlsquare

Carlsquare is a Pan-European research firm and financial advisor, focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 80+ employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team have an extensive experience about the stock
environment and several business sectors. The team produces company research reports,
independent valuations and trading notes. The group have offices in Berlin, Copenhagen,
Hamburg, London, Munich and Stockholm. Read more

Contact
MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Contacts

MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20
 
JONATAN ANDERSSON
Equity Analyst
jonatan.andersson@carlsquare.com
+46 (0)70 508 00 51

Attachments

Research update, DanCann Pharma Q2 2021: Transformative acquisition adds great value